Ascletis has filed two Investigational New Drug applications with the US FDA for new obesity treatments, including a peptide-based injection and a co-formulation.
Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
